In BRIP1 carriers and mutation-negative, intermediate risk women (5–10% lifetime ovarian cancer risk) with a strong family history, it may be delayed until 45–50 years (Appendix I).29,30 A significant number of women undergoing RRSO will end up with premature iatrogenic menopause (with the average age of natural menopause being 51 years) requiring HRT. Here, BRIP1 is linked to ovarian carcinoma.